Dublin, Nov. 01, 2018 (GLOBE NEWSWIRE) -- The "Cancer Supportive Care Drugs Market Analysis Report By Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs), By Major Markets, Vendor Landscape, And Segment Forecasts, 2016 - 2022" report has been added to ResearchAndMarkets.com's offering.

The global cancer supportive care drugs market size is expected to be valued at USD 23.5 billion by 2022, progressing at a CAGR of 1.8% during the forecast period.

The market is anticipated to be driven by large number of side-effects associated with cancer treatment, increasing uptake of biosimilars, rising expenditure on healthcare, and availability of effective treatment methods, including target specific and tailored treatments.

Chemotherapy and radiotherapy are traditional methods for cancer treatment with approximately four million people receiving chemotherapy every year. Supportive care products are essential to prevent and manage symptoms and side-effects of cancer and its treatment.Among major cancer types, lung and breast cancers are the most prominent cancer type with the highest demand for supportive care drugs.

G-CSFs and ESAs therapeutic classes are witnessing a fundamental shift from biologics to biosimilars. The market for cancer pain, chemotherapy induced nausea and vomiting, and cancer induced bone diseases will grow significantly during the forecast period, due to new product launches and high unmet needs. The cancer pain market is estimated to witness a shift from opioids to non-opioids therapies. The shift will be backed by patent loss, high mortality, addiction, and major safety issues associated with narcotic agents.

Further key findings from the report suggest:

• Some of the key players operating in this industry are Amgen, Johnson & Johnson, Merck, Roche, Helsinn Healthcare, Heron Pharma, and Tesaro
• Among EU5, Germany captured the second position in the global cancer support care drugs market. Japan is poised to witness the fastest growth over the forecast period
• The CINV drugs market will be propelled by widening base of patients, increasing adoption of chemotherapeutic drugs, and launch of new drug delivery approaches to improve patient compliance
• In Europe, Zarzio has taken over its reference product Neupogen in terms of market share
• Late stage pipeline products include non-opioids such as Tanezumab and HTX-011
• Newer immunotherapies directed against PD-1 ligands and PD-L1 proteins have shown to be more effective with a superior safety profile

Key Topics Covered:

Chapter 1 Research Methodology
1.1. Information procurement
1.2. Information or Data Analysis
1.2.1. Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology
3.1. Disease Primer
3.1.1. Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S., Japan, EU5)

Chapter 4 Global Cancer supportive care drugs market Overview
4.1. Major Therapeutic Classes for Cancer Supportive Care
4.2. Market, by Therapeutic Class
4.3. Market Size and Forecast (2016 - 2022)
4.4. Market Size and Forecast, by Seven Major Markets (2016 - 2022)
4.5. Market Share Distribution, by Company (2016 - 2022)
4.6. Sales Performance, by Drug Class (2016 - 2022)
4.6.1. Granulocyte Colony Stimulating Factors - Chemotherapy Induced Neutropenia (CIN)
4.6.2. Erythropoietin Stimulating Agents (ESAs) for Chemotherapy Induced Anemia (CIA)
4.6.3. Anti-emetics for Chemotherapy Induced Nausea and Vomiting (CINV)
4.6.4. Bisphosphonates for Cancer Induced Bone Diseases
4.6.5. Opioids and NSAIDs for Cancer Pain
4.7. Market Dynamics and Brand Strategies
4.8. Patent Expiry Analysis
4.9. Cancer supportive care drugs market: Drivers and Restraints
4.9.1. Market Drivers
4.9.2. Market Challenges
4.10. M&A, Deal Landscape (2013-2017 YTD)
4.10.1. Mergers & Acquisitions
4.10.2. Deals Landscape
4.11. Evolution of Biosimilars
4.12. Emerging Markets
4.13. Pricing and Reimbursement Scenario
4.14. Cancer Supportive Care Sector SWOT

Chapter 5 Global Cancer Supportive Care Pipeline Intelligence
5.1. Pipeline Landscape
5.2. Leading Drugs in Development
5.3. Key R&D Trends
5.4. Pipeline Landscape
5.4.1. Late Stage Pipeline Drugs
5.5. Profiles of Disruptive Drugs
5.6. Global Pipeline Forecast

Chapter 6 Company Profiles

Chapter 7 Market Outlook
7.1. What the Future Holds
7.2. The Winners and Losers
7.3. Emerging Companies/New Technology Platforms
7.4. The Road Ahead

Companies Mentioned

• Amgen
• Merck
• Helsinn Healthcare
• Johnson & Johnson
• Heron Pharma
• Roche
• Novartis (Sandoz)
• Tesaro

For more information about this report visit https://www.researchandmarkets.com/research/6tbsgn/global_cancer?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs